JP6698681B2 - 糖タンパク質のグリカン含量のレベルを操作するためのプロセス - Google Patents

糖タンパク質のグリカン含量のレベルを操作するためのプロセス Download PDF

Info

Publication number
JP6698681B2
JP6698681B2 JP2017547931A JP2017547931A JP6698681B2 JP 6698681 B2 JP6698681 B2 JP 6698681B2 JP 2017547931 A JP2017547931 A JP 2017547931A JP 2017547931 A JP2017547931 A JP 2017547931A JP 6698681 B2 JP6698681 B2 JP 6698681B2
Authority
JP
Japan
Prior art keywords
cells
cell
cell culture
perfusion
recombinant protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017547931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538446A (ja
JP2017538446A5 (OSRAM
Inventor
ライスク，ダニエル・アール
トレンタランジ，マイケル・ティー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6698681(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2017538446A publication Critical patent/JP2017538446A/ja
Publication of JP2017538446A5 publication Critical patent/JP2017538446A5/ja
Application granted granted Critical
Publication of JP6698681B2 publication Critical patent/JP6698681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017547931A 2014-12-01 2015-12-01 糖タンパク質のグリカン含量のレベルを操作するためのプロセス Active JP6698681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
US62/085,759 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080270A Division JP7066775B2 (ja) 2014-12-01 2020-04-30 糖タンパク質のグリカン含量のレベルを操作するためのプロセス

Publications (3)

Publication Number Publication Date
JP2017538446A JP2017538446A (ja) 2017-12-28
JP2017538446A5 JP2017538446A5 (OSRAM) 2019-01-17
JP6698681B2 true JP6698681B2 (ja) 2020-05-27

Family

ID=55024253

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017547931A Active JP6698681B2 (ja) 2014-12-01 2015-12-01 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2020080270A Active JP7066775B2 (ja) 2014-12-01 2020-04-30 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2022072126A Pending JP2022101669A (ja) 2014-12-01 2022-04-26 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2024063188A Pending JP2024095777A (ja) 2014-12-01 2024-04-10 糖タンパク質のグリカン含量のレベルを操作するためのプロセス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020080270A Active JP7066775B2 (ja) 2014-12-01 2020-04-30 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2022072126A Pending JP2022101669A (ja) 2014-12-01 2022-04-26 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2024063188A Pending JP2024095777A (ja) 2014-12-01 2024-04-10 糖タンパク質のグリカン含量のレベルを操作するためのプロセス

Country Status (22)

Country Link
US (5) US10167492B2 (OSRAM)
EP (2) EP3227454B1 (OSRAM)
JP (4) JP6698681B2 (OSRAM)
KR (1) KR102623965B1 (OSRAM)
CN (1) CN107109455B (OSRAM)
AU (5) AU2015355087C1 (OSRAM)
CA (1) CA2969225C (OSRAM)
CL (1) CL2017001369A1 (OSRAM)
CY (1) CY1123247T1 (OSRAM)
DK (1) DK3227454T3 (OSRAM)
EA (2) EA202091598A3 (OSRAM)
ES (1) ES2784503T3 (OSRAM)
HU (1) HUE049201T2 (OSRAM)
IL (2) IL276165B (OSRAM)
LT (1) LT3227454T (OSRAM)
MX (1) MX385409B (OSRAM)
PL (1) PL3227454T3 (OSRAM)
PT (1) PT3227454T (OSRAM)
SG (2) SG10202002458PA (OSRAM)
SI (1) SI3227454T1 (OSRAM)
WO (1) WO2016089919A1 (OSRAM)
ZA (2) ZA201703729B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3227454B1 (en) 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
CN110418846A (zh) * 2017-03-14 2019-11-05 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制
EP3601586A1 (en) * 2017-03-31 2020-02-05 Boehringer Ingelheim International GmbH Perfusion medium
CN111373028B (zh) * 2017-11-30 2022-07-05 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
SG11202009216YA (en) * 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
JP2021524745A (ja) * 2018-05-24 2021-09-16 アレス トレーディング ソシエテ アノニム 糖タンパク質組成物の非フコシル化レベルを制御する方法
MX2020013036A (es) 2018-06-05 2021-02-26 Amgen Inc Modulacion de la fagocitosis celular dependiente de anticuerpos.
US20220033511A1 (en) 2018-09-11 2022-02-03 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
CA3117447C (en) 2018-11-13 2024-06-04 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
MX2021008030A (es) * 2018-12-31 2021-08-05 Momenta Pharmaceuticals Inc Metodos para producir ustekinumab.
US20220098279A1 (en) * 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
BR112021022202A2 (pt) 2019-05-06 2021-12-28 Amgen Inc Modulação de funções efetoras de anticorpo
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
CN116391043A (zh) * 2020-08-14 2023-07-04 百时美施贵宝公司 蛋白质的制造方法
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
WO2023161885A1 (en) * 2022-02-25 2023-08-31 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025036924A1 (en) * 2023-08-16 2025-02-20 Glaxosmithkline Intellectual Property Limited Method of controlling antibody glycosylation profile

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
KR101004174B1 (ko) 1995-06-29 2010-12-24 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP3029062A1 (en) 2000-05-26 2016-06-08 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
US20100028904A1 (en) * 2007-03-30 2010-02-04 Centocor, Inc. Way to obtain high expression clones of mammalian cells using a methylcellulose with fluorescent protein a or g and fluorescent screening method
US20100113294A1 (en) 2007-04-16 2010-05-06 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
DE602008006410D1 (de) 2007-06-15 2011-06-01 Amgen Inc Verfahren zur behandlung von zellkulturmedien für die verwendung in einem bioreaktor
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
WO2012054654A2 (en) 2010-10-20 2012-04-26 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
MX2013009741A (es) 2011-02-23 2014-01-17 Amgen Inc Medio de cultivo celular para exposicion a uvc y metodos relacionados al mismo.
AU2012226398B9 (en) * 2011-03-06 2017-04-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2702077A2 (en) * 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
HUE033279T2 (en) 2011-07-01 2017-11-28 Amgen Inc Mammalian cell culture
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
WO2013040444A1 (en) 2011-09-16 2013-03-21 Amgen Inc. Pre-programmed non-feedback controlled continuous feeding of cell cultures
JP6526414B2 (ja) 2011-10-26 2019-06-05 アムジエン・インコーポレーテツド Ｕｖ光曝露から生じるタンパク質の改変と分解を減ずるまたは排除する方法
CN104487570A (zh) * 2012-01-20 2015-04-01 新加坡科技研究局 Cho-gmt重组蛋白的表达
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
JP6273205B2 (ja) * 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2014294618B2 (en) 2013-07-23 2019-06-27 Biocon Limited Methods for controlling fucosylation levels in proteins
DK3110961T3 (da) 2014-02-27 2020-02-03 Hoffmann La Roche Modulering af cellevækst og glycosylering i rekombinant glycoproteinproduktion
WO2016068799A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
EP3227454B1 (en) 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein

Also Published As

Publication number Publication date
AU2025223948A1 (en) 2025-09-18
US20200172947A1 (en) 2020-06-04
EP3227454B1 (en) 2020-01-29
WO2016089919A1 (en) 2016-06-09
IL252569B (en) 2020-08-31
HUE049201T2 (hu) 2020-09-28
KR20170083636A (ko) 2017-07-18
CL2017001369A1 (es) 2018-02-23
EP3680344A1 (en) 2020-07-15
IL276165B (en) 2022-11-01
AU2015355087C1 (en) 2025-10-30
PT3227454T (pt) 2020-04-06
EP3227454A1 (en) 2017-10-11
US10167492B2 (en) 2019-01-01
ES2784503T3 (es) 2020-09-28
US20210017565A1 (en) 2021-01-21
SG11201704351WA (en) 2017-06-29
US10822630B2 (en) 2020-11-03
JP2024095777A (ja) 2024-07-10
EA202091598A3 (ru) 2021-01-29
US20170362625A1 (en) 2017-12-21
JP2017538446A (ja) 2017-12-28
AU2020202302A1 (en) 2020-04-23
JP2022101669A (ja) 2022-07-06
CA2969225C (en) 2023-08-22
KR102623965B1 (ko) 2024-01-11
US20190085370A1 (en) 2019-03-21
CN107109455A (zh) 2017-08-29
AU2015355087B2 (en) 2020-04-09
AU2015355087A1 (en) 2017-06-29
MX2017006997A (es) 2017-10-16
AU2024204313A1 (en) 2024-07-11
JP2020124216A (ja) 2020-08-20
IL276165A (en) 2020-09-30
PL3227454T3 (pl) 2020-07-27
CN107109455B (zh) 2022-02-18
SG10202002458PA (en) 2020-04-29
CA2969225A1 (en) 2016-06-09
EA201791223A1 (ru) 2017-10-31
CY1123247T1 (el) 2021-10-29
EA202091598A2 (ru) 2020-10-30
ZA202006002B (en) 2022-03-30
SI3227454T1 (sl) 2020-06-30
ZA201703729B (en) 2021-03-31
EA036178B1 (ru) 2020-10-09
LT3227454T (lt) 2020-07-27
JP7066775B2 (ja) 2022-05-13
BR112017011652A2 (pt) 2018-06-26
AU2022200586A1 (en) 2022-02-24
DK3227454T3 (da) 2020-04-14
US20230159974A1 (en) 2023-05-25
IL252569A0 (en) 2017-07-31
MX385409B (es) 2025-03-04

Similar Documents

Publication Publication Date Title
US20230159974A1 (en) Process for manipulating the level of glycan content of a glycoprotein
US11427848B2 (en) Methods for harvesting mammalian cell cultures
HK40034016A (en) Process for manipulating the level of glycan content of a glycoprotein
HK40065682B (en) Methods for harvesting mammalian cell cultures
HK40065682A (en) Methods for harvesting mammalian cell cultures
BR112017011652B1 (pt) Método para manipulação do nível de teor de glicano fucosilado em uma proteína recombinante
HK40014805B (en) Methods for harvesting mammalian cell cultures
HK40014805A (en) Methods for harvesting mammalian cell cultures

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200428

R150 Certificate of patent or registration of utility model

Ref document number: 6698681

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250